[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res; 2005 Oct 1;65(19):8984-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
  • The development of effective, systemic therapies for metastatic cancer is highly desired.
  • We show here that the systemic delivery of sequence-specific small interfering RNA (siRNA) against the EWS-FLI1 gene product by a targeted, nonviral delivery system dramatically inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
  • The nonviral delivery system uses a cyclodextrin-containing polycation to bind and protect siRNA and transferrin as a targeting ligand for delivery to transferrin receptor-expressing tumor cells.
  • [MeSH-major] Oncogene Proteins, Fusion / antagonists & inhibitors. Proto-Oncogene Protein c-fli-1 / antagonists & inhibitors. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. Sarcoma, Ewing / therapy
  • [MeSH-minor] Animals. Cell Growth Processes / genetics. Cell Line, Tumor. Disease Models, Animal. Down-Regulation. Female. Gene Silencing. Luciferases / biosynthesis. Luciferases / genetics. Mice. Mice, Inbred C57BL. Mice, Inbred NOD. Mice, SCID. Neoplasm Metastasis. RNA-Binding Protein EWS. Receptors, Transferrin / metabolism. Transduction, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204072.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA, Small Interfering; 0 / RNA-Binding Protein EWS; 0 / Receptors, Transferrin; EC 1.13.12.- / Luciferases
  •  go-up   go-down


2. Pamukçu B, Bilge AK, Meriç M, Atilgan D: Metastatic Ewing's sarcoma involving the right ventricle. Turk Kardiyol Dern Ars; 2008 Dec;36(8):546-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Ewing's sarcoma involving the right ventricle.
  • Cardiac metastasis of Ewing's sarcoma is rare.
  • She had a seven-year history of radical right tibial resection for Ewing's sarcoma and was also receiving chemotherapy for lung metastasis of Ewing's sarcoma.
  • The mass showed partial contrast enhancement, suggesting a malignant metastatic mass.
  • [MeSH-major] Bone Neoplasms / pathology. Echocardiography / methods. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Sarcoma, Ewing / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223721.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


3. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res; 2008 Aug 1;14(15):4850-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Patients with metastatic or recurrent Ewing's sarcoma family of tumors and alveolar rhabdomyosarcoma have <25% 5-year survival in most studies.
  • EXPERIMENTAL DESIGN: Fifty-two patients with translocation positive, recurrent, or metastatic Ewing's sarcoma family of tumors or alveolar rhabdomyosarcoma underwent prechemotherapy cell harvest via apheresis for potential receipt of immunotherapy.
  • All cohorts received autologous T cells, influenza vaccinations, and dendritic cells pulsed with peptides derived from tumor-specific translocation breakpoints and E7, a peptide known to bind HLA-A2.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):227-31 [9028550.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):53-61 [16412789.001]
  • [Cites] J Clin Invest. 1998 May 15;101(10):2290-6 [9593785.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):455-62 [9664088.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1021-7 [10419894.001]
  • [Cites] Exp Hematol. 1999 Oct;27(10):1477-86 [10517488.001]
  • [Cites] Clin Exp Med. 2004 Oct;4(2):78-85 [15672944.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jun;54(6):526-34 [15838707.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):930-9 [15776111.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):505-16 [16113607.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):749-56 [16136047.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Oncologist. 1999;4(5):370-8 [10551553.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1669-78 [10587357.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • [Cites] J Exp Med. 2001 Jan 15;193(2):233-8 [11208863.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1818-23 [16452243.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3089-94 [16809734.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):132-9 [16317751.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):356-61 [17264330.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1842-52 [17293384.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jul;56(7):1037-46 [17149595.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2812-20 [11387352.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3649-59 [11504746.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6868-75 [11559563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):931-6 [11792864.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):158-64 [11836714.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):221-4 [11846300.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):169-89 [11856593.001]
  • [Cites] Cytotherapy. 2001;3(1):19-29 [12028840.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):347-53 [12632347.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):579-86 [14614331.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):120-5 [15075902.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):44-50 [6850544.001]
  • [Cites] Immunol Today. 1990 Nov;11(11):406-10 [2078294.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):442-6 [2009059.001]
  • [Cites] Adv Immunol. 1991;49:281-355 [1853786.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):143-9 [7800006.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4609-16 [8648103.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] J Immunol. 1997 Oct 15;159(8):3823-37 [9378970.001]
  • (PMID = 18676758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 SC010289-08; United States / PHS HHS / / N01-C0-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS42930; NLM/ PMC2497450
  •  go-up   go-down


Advertisement
4. Dimou AT, Syrigos KN, Saif MW: Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP; 2010;11(2):135-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
  • Surgical excision has been the mainstay of treatment for neuroendocrine tumors of the pancreas (PNET).
  • Compounds like streptozocin and dacarbazin have been traditionally used in inoperable cases and somatostatin to treat syndromes deriving from functional tumors.
  • However, a lot of progress has taken place in the area of molecular characterization of these tumors, revealing activation of mammalian target of rapamycin (mTOR) and VEGF pathways.
  • The role of modern biologic compounds in the treatment of PNET is not clear yet.
  • In addition, combination of resection and transarterial chemoembolization (TACE) has been proven effective over either modality alone in the treatment of PNET metastatic to the liver in a retrospective analysis.
  • This comes to address the problem of selecting local intervention in a metastatic disease, which has been a reasonable choice for this group of tumors in the past.
  • Last but not least the role of Ki-67 in decision-making in PNET is being discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Medical Oncology / trends. Neuroendocrine Tumors / drug therapy. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208321.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 23
  •  go-up   go-down


5. Drabko K, Zawitkowska-Klaczynska J, Wojcik B, Choma M, Zaucha-Prazmo A, Kowalczyk J, Gorczynska E, Toporski J, Kałwak K, Turkiewicz D, Chybicka A: Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma. Pediatr Transplant; 2005 Oct;9(5):618-21
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma.
  • Twenty-one children with high-risk Ewing's tumor received high-dose chemotherapy with a PBSCT.
  • Megachemotherapy with PBSCT is a safe procedure in children with Ewing's sarcoma in remission.
  • Autologos transplantation in children with metastatic Ewing's sarcoma seems to improve their outcome.
  • Patients with Ewing's sarcoma, resistant to conventional therapy and with recurrent disease did not benefit from megachemotherapy.
  • New approaches such as anti-tumor vaccination or using of imatinib are reasonable to introduce in patients with relapsed or resistant to therapy Ewing's tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Sarcoma, Ewing / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176419.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


6. Hui SK, Verneris MR, Froelich J, Dusenbery K, Welsh JS: Multimodality image guided total marrow irradiation and verification of the dose delivered to the lung, PTV, and thoracic bone in a patient: a case study. Technol Cancer Res Treat; 2009 Feb;8(1):23-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with metastatic Ewing's sarcoma underwent MRI, and bone scan imaging prior to TMI.
  • [MeSH-major] Bone Marrow / radiation effects. Lung / radiation effects. Radiotherapy, Intensity-Modulated / methods. Sarcoma, Ewing / radiotherapy. Thoracic Vertebrae / radiation effects. Tomography, Spiral Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19166239.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 1 K12-HD055887-01
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Gholamrezanezhad A, Moinian D, Mirpour S, Hajimohammadi H: Unilateral pulmonary metastases from Ewing's sarcoma shown in a technetium-99m-methylene-diphosphonate bone scan. Hell J Nucl Med; 2006 Sep-Dec;9(3):181-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral pulmonary metastases from Ewing's sarcoma shown in a technetium-99m-methylene-diphosphonate bone scan.
  • CT-guided biopsy of this mass led to a diagnosis of metastatic Ewing's sarcoma.
  • Although lung uptake on bone scans has been noted in various occasions (such as: pulmonary alveolar microlithiasis, Pneumocystis carinii pneumonia, and various tumoral lesions), increased uptake of (99m)Tc-MDP in lung metastases of Ewing's sarcoma has not been reported according to our knowledge until now.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Sarcoma, Ewing / radionuclide imaging. Sarcoma, Ewing / secondary. Technetium Tc 99m Medronate

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160160.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


8. Hendershot E: Treatment approaches for metastatic Ewing's sarcoma: a review of the literature. J Pediatr Oncol Nurs; 2005 Nov-Dec;22(6):339-52
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment approaches for metastatic Ewing's sarcoma: a review of the literature.
  • The Ewing's sarcoma family of tumors (ESFT) is an aggressive group of neoplasms that represent approximately 3% of all pediatric malignancies.
  • The outcome for the 25% of patients who present with metastatic disease, however, remains poor, with long-term survival rates of less than 30%.
  • Outcomes of metastatic treatment protocols to date will be examined as well as the rationale for current and future therapies.
  • Nursing considerations in caring for patients with metastatic ESFT will be discussed.
  • Cancer therapy in general is becoming more complex; treatment approaches involve different ways of targeting tumor cells.
  • [MeSH-major] Neoplasm Metastasis / drug therapy. Sarcoma, Ewing / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216896.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


9. Leblebicioglu G: Reliability of vascularized fibula in maintaining arthrodesis following extra-articular wide excisions of malignant musculoskeletal tumors. Saudi Med J; 2006 Aug;27(8):1204-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reliability of vascularized fibula in maintaining arthrodesis following extra-articular wide excisions of malignant musculoskeletal tumors.
  • OBJECTIVE: To evaluate the reliability of vascularized fibula transfer in maintaining arthrodesis following wide excision of malignant tumors located at the metaphyseal ends of long bones.
  • The most common diagnosis was malignant giant cell tumor (6), followed by Ewing's sarcoma (3), hemangioendothelioma (2), osteosarcoma (2) and chondrosarcoma (1).
  • Three tumors were located at the distal end of the radius, 4 at the proximal humerus, 3 at the distal femur, one at the proximal tibia, one in distal tibia, one in distal humerus and one in proximal ulna.
  • Two patients with metastatic Ewing's sarcoma had metastatic disease.
  • CONCLUSION: Vascularized fibula transfer is reliable to achieve arthrodesis following extra-articular excision of malignant tumors from the metaphyseal ends.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Saudi Med J. 2007 Jun;28(6):984 [17530131.001]
  • (PMID = 16883453.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


10. Aslam E, Imran M, Faridi NM: Bilateral parietal extradural metastatic Ewing's sarcoma simulating acute epidural hematoma. J Coll Physicians Surg Pak; 2006 Aug;16(8):543-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral parietal extradural metastatic Ewing's sarcoma simulating acute epidural hematoma.
  • The following case report describes an unusual metastasis of Ewing's sarcoma to extradural parietal region bilaterally.
  • [MeSH-major] Bone Neoplasms / pathology. Hematoma, Epidural, Cranial / diagnosis. Sarcoma, Ewing / secondary

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899187.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


11. Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, Stine K, Nicholas R, Perlman EJ, Dubowy R, Wainer IW, Dickman PS, Link MP, Goorin A, Grier HE, Pediatric Oncology Group, Children's Cancer Group Phase II Study 9457, Children's Oncology Group: Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. J Clin Oncol; 2006 Jan 1;24(1):152-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
  • PURPOSE: Prognosis is poor for Ewing sarcoma patients with metastasis at diagnosis.
  • PATIENTS AND METHODS: Eligible patients were < or = 30 years old and had histologically proven Ewing sarcoma or primitive neuroectodermal tumor (PNET) and metastasis at diagnosis.
  • CONCLUSION: Topotecan had limited activity in patients with Ewing sarcoma or PNET metastatic at diagnosis.
  • [MeSH-major] Amifostine / therapeutic use. Bone Neoplasms / drug therapy. Cyclophosphamide / administration & dosage. Sarcoma, Ewing / drug therapy. Topotecan / therapeutic use

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382125.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide; M487QF2F4V / Amifostine
  •  go-up   go-down


12. Dumont SN, Aslam MI, McAuliffe JC, Yang D, Nolden LK, Oyedeji CO, Trent JC: CXCR4-CXCL12 axis: Pivotal role as a metastatic mediator in small cell sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4-CXCL12 axis: Pivotal role as a metastatic mediator in small cell sarcoma.
  • : 10569 Background: The chemokine CXCL12, and its receptor CXCR4, are expressed in over 23 different types of cancers, and have been associated with the metastatic phenotype and inferior clinical outcomes.
  • Given the poor prognosis after failure of front-line therapy for patients with metastatic Ewing's sarcoma (EWS) and rhabdomyosarcoma (RMS), we examined the functional role of CXCR4 in these small cell sarcoma in vitro.
  • RESULTS: CXCR4 was highly expressed on 46 % of human RMS tumor samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963792.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Brames M, Ehrlich Y, Einhorn L: Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with PNET based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with PNET based chemotherapy.
  • : e16121 Background: Metastatic testis cancer is uniquely chemosensitive and highly curable.
  • We report results of malignant transformation of teratoma to metastatic PNET treated with PNET based chemotherapy.
  • METHODS: Retrospective review of 42 patients with PNET in testis or at metastatic sites seen at Indiana University from 1999-2007.
  • Of these 42 patients, 10 had inoperable or unresectable PNET treated with cyclophosphamide 1200 mg/M<sup>2</sup>, doxorubicin 75 mg/M<sup>2</sup>, and vincristine 2 mg IV alternating with ifosfamide 1.8 grams/M<sup>2</sup> × 5 days plus etoposide 100 mg/M<sup>2</sup> × 5 days.
  • RESULTS: 9 of 10 patients had at least 1 prior platinum based combination chemotherapy regimen for their germ cell tumor.
  • Tumor markers (human chorionic gonadotropin and alphafetoprotein) were normal at start of chemotherapy for biopsy proven PNET.
  • Two of 10 are currently disease-free for 16 and 33 months from initiation of PNET specific chemotherapy and 3 other patients are alive with disease at 73, 34, and 30 months.
  • CONCLUSIONS: PNET specific chemotherapy has a high objective response rate for malignant transformation of teratoma to PNET, with some patients capable of long-term survival with chemotherapy followed by surgical resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963389.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Schwinger W, Klass V, Benesch M, Lackner H, Dornbusch HJ, Sovinz P, Moser A, Schwantzer G, Urban C: Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol; 2005 Jul;16(7):1199-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The administration of high-dose interleukin-2 (IL-2) seems to be a therapeutic option for children with refractory and metastatic solid malignancies.
  • METHODS: We prospectively studied treatment-related toxicities, quality of life and laboratory parameters in 10 children with progressive or metastatic solid tumors (metastatic osteosarcoma, n=4; neuroblastoma stage IV, n=3; metastatic Ewing's sarcoma, n=2; metastatic Wilms' tumor, n=1) during IL-2 therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849223.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


15. Teh SH, Deveney C, Sheppard BC: Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg; 2007 May;193(5):610-3; discussion 613
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
  • BACKGROUND: Benign and malignant pancreatic neuroendocrine tumors (PNETs) are rare, and long-term outcome is generally poor without surgical intervention.
  • The aim of the study was to assess whether aggressive pancreatic resection is justifiable for patients with PNET.
  • Mean tumor size was 4.2 cm, and multiple tumors were noted in 10 patients.
  • CONCLUSIONS: Aggressive pancreatic resection for PNET can be performed with low perioperative mortality and morbidity.
  • In patients with malignant PNET, metastatic recurrence is not uncommon and will usually require additional multimodality therapy.
  • When possible, an aggressive approach to PNET is justified to optimize palliation and survival.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery


16. Kumar R, Giri PJ: Pediatric extradural spinal tumors. Pediatr Neurosurg; 2008;44(3):181-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric extradural spinal tumors.
  • We have reviewed 16 children with extradural spinal tumors, both benign and malignant, treated from 1998 to 2006 in Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
  • The duration of symptoms was 2-18 months, relatively longer in benign (mean 9.5 months) than malignant (mean 4.2 months) tumors.
  • There was deterioration from grade III to grade IV in 2 patients (PNET + metastatic adenocarcinoma) and 2 patients (neuroblastoma + Ewing's sarcoma) maintained their grades of IV and V, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334840.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Saran F, Baumert BG, Creak AL, Warrington AP, Ashley S, Traish D, Brada M: Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET. Pediatr Blood Cancer; 2008 Mar;50(3):554-60
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
  • PURPOSE: To evaluate the efficacy and toxicity of hypofractionated stereotactic radiotherapy in the management of locally recurrent or residual central nervous system (CNS) primitive neuroectodermal tumors (PNETs).
  • PATIENTS AND METHODS: Between 1991 and 2005, 12 patients with locally recurrent medulloblastoma and two patients with residual supratentorial PNET were treated with hypofractionated stereotactic conformal radiotherapy (SCRT).
  • Causes of death were recurrent CNS disease (n = 7), herpes encephalitis (n = 1), and metastatic PNET outside the CNS (n = 1).
  • CONCLUSION: Hypofractionated SCRT provides effective local control with acceptable toxicity for patients with recurrent localized PNET.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Dose Fractionation. Medulloblastoma / radiotherapy. Neuroectodermal Tumors, Primitive / radiotherapy. Radiotherapy, Conformal / methods. Supratentorial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17941071.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Nissen NN, Kim AS, Yu R, Wolin EM, Friedman ML, Lo SK, Wachsman AM, Colquhoun SD: Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am Surg; 2009 Oct;75(10):1025-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
  • Pancreatic neuroendocrine tumors (pNETs) are an uncommon pancreatic neoplasm.
  • Over this time period, 154 patients with carcinoid and neuroendocrine tumors were treated, which included 46 patients (30% of total) with pNETs.
  • Fourteen patients had functional tumors.
  • At the time of diagnosis, 22 patients (48%) presented without metastases and 24 (52%) had metastatic disease.
  • All patients with nonmetastatic pNET underwent pancreatic resection with 95 per cent postoperative survival.
  • In patients presenting with metastatic pNET, multiple treatment modalities were used, including liver resection or ablation (n = 15), hepatic chemoembolization (n = 17), pancreatic resection (n = 12), and systemic treatments (n = 7).
  • Pancreatic resection results in greater than 80 per cent 3-year survival in nonmetastatic pNET.
  • In patients presenting with metastatic pNET, excellent survival rates are also achievable using a multidisciplinary multimodal approach.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886158.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Geramizadeh B, Makarempour A, Foroughi AA: Fine needle aspiration of a breast mass caused by metastatic Ewing's sarcoma. Acta Cytol; 2010 Mar-Apr;54(2):237-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of a breast mass caused by metastatic Ewing's sarcoma.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391990.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement